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Abstract Before age 65, women have less heart disease
than men. For many years, estrogen was the most popular
explanation for this female advantage, and observational
studies through the 1980s showed a lower risk of heart
attacks in postmenopausal women taking “replacement”
estrogen. But the Women’s Health Initiative (WHI), the first
placebo-controlled trials of hormone therapy with the size
and statistical power necessary to study clinical cardiovas-
cular outcomes, did not confirm the hormone-healthy heart
hypothesis. Now, at least 5 years later, the most unexpected
WHI result may be how resilient the estrogen hypothesis
has been. Where, beyond estrogen therapy, should we go
from here to explain the striking sex differences in heart
disease rates? A broader spectrum of research about the
female cardiovascular advantage and its translation is
needed.
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Before age 65, women have less heart disease than men in
every country in the world where data exist and heart
disease rates are high enough for stable estimates [7]. This
is true whether heart disease risk factor levels are high or
low and whether heart disease incidence rates are high or
low and despite differences in access to effective medical or
surgical therapies.
The universality of this male/female difference suggests
that it is not explained by stress or the Western diet,
sedentary lifestyle, or tobacco use. Instead, these differ-
ences point to some intrinsic and universal sex character-
istic (biologic) and are unlikely to reflect gender
(psychosocial) differences.
For many years, estrogen has been the most popular
explanation for the female advantage. This thesis was
initially based on castrate animal models and autopsy
studies of oophorectomized women. These studies are
problematic because sex differences in atherosclerosis do
not occur naturally in intact animal models, and oophorec-
tomized young women have lost not only estrogen but also
testosterone and progesterone and other less studied ovarian
hormones such as inhibin, plus their ability to have babies.
By the 1960s, the evidence that estrogen was cardiopro-
tective was so compelling that a clinical trial was designed
to test the benefit of treating men at high risk of a heart
attack with estrogen. Because no one had any idea what
was the optimal dose of estrogen for men, men were treated
with very large doses, enough to cause gynecomastia,
impotence, and venous thromboembolic disease [5]. Estro-
gen did not prevent heart attacks in men. This trial was
stopped early [5].
During the next 20 years, many large observational studies
in postmenopausal women showed a lower risk of heart
attacks in women taking “replacement” estrogen. Animal and
in vitro studies suggested a plethora of potential protective
mechanisms, as did studies showing that estrogen treatment
improved high-density lipoprotein cholesterol (the good
lipoprotein with a sex difference) in women.
In the 1970s, the Food and Drug Administration refused
to grant industry permission to say that postmenopausal
estrogen could be used to prevent heart disease. This
decision prompted the Women’s Health Initiative (WHI),
the first placebo-controlled trials of hormone therapy with
the size and statistical power necessary to study clinical
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gen plus progestin [8] or estrogen alone [1]) confirmed the
hormone-healthy heart hypothesis. Conjugated equine
estrogen, the most commonly used oral estrogen (plus a
progestogen), was bad for women’s hearts or (for estrogen
alone) was neutral. Both regimens increased the risk of
stroke and venous thromboembolic disease. These trials
were stopped early [3].
Now, at least 5 years later, the most unexpected WHI
result may be how resilient the estrogen hypothesis has
been. Explanations for the trials’“ failure” (to show what
was expected) spawned many theories, most notably the
narrow window of opportunity for hormone cardiovascular
disease benefit implied by the “timing hypothesis,” and
spawned new estrogen studies with lower doses, and
different regimens or routes of administration [4]. The
results of these new trials are eagerly awaited, but none will
have the size or duration needed to show a significant
reduction in clinical events in relatively young women [4].
Also, because estrogens are carcinogens [6], it seems
unlikely that estrogen for heart disease prevention will ever
again be America’s best-selling prescription product.
Although the results of the WHI were unwelcome, the
trials were not a failure. WHI results spared millions of older
women years of ineffective and potentially unsafe estrogen
therapy. The WHI alsoraised women’s (andtheir physicians’)
awareness of the dangers of heart disease in both sexes.
Where, beyond hormone replacement therapy, should we
go from here to explain the striking sex differences in heart
disease rates? Although several important questions are
raised in this special issue on women and cardiovascular
disease of the Journal of Cardiovascular Translational
Research, some simple questions are not addressed here
and have been largely neglected elsewhere.
One of my favorite unaddressed questions is why is the
universal sex difference in cardiovascular events (unex-
plained by tobacco habit) restricted to the coronary arteries?
Why is no similar universal sex difference observed for
stroke? What is different about the female coronary
arteries? Is it anatomy, such as, small women have small
arteries, with different branching angles and more micro-
vasculature, or is it physiology, such as, vasoreactivity,
nitric oxide, or different remodeling [2]? Could some of
these differences be necessary to meet women’s unique
compensatory needs during pregnancy, with its large
demands on the circulation?
Orcould theheartdiseasesexdifference beexplainedbya
specifically adapted immune system, necessary to retain an
antigenically foreign fetus and complete a successful
pregnancy? Compared to men, women are more prone to
several autoimmune diseases; what is this telling us about
theirinflammatoryresponses,susceptibilitytoinflammation,
and heart attacks?
Candidate explanatory mechanisms for sex differences in
heart disease should fit what we know about other sex
differences; pregnancy is one obvious and biologically
plausible area, but by no means the only opportunity. The
supply of questions about sex differences in coronary artery
diseaseislarge.ThisnewAmericanHeartAssociationjournal
can offer a forum for a broader spectrum of research about the
female cardiovascular advantage and its translation, possibly
from bedside to bench.
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